Member Info for chester18

Do we know exactly what we're waiting for? Surely whatever the issue Ichor and Scancell have had adequate time to answer any amount of questions. Or, is it that the FDA are dragging their heels and if so what could be the reason...? Doe's anyone have a view? Chester

The delay in trial approval from the FDA now feels to me to be overdone. I don't have the actual date but we've now been waiting 5 or maybe 6 months. Do we know exactly what we're waiting for? Surely whatever the issue Ichor and Scancell have had adequate time to answer any amount of questions. Or, is it that the FDA are dragging their heels and if so what could be the reason...? Chester

Unless another deal is announced the share price will now consolidate up to the 26th when the expected positive update will evaporate fears that the effects could be sort lived. But, if that positive news is released you can expect the share to quite possibly double very quickly. We are still not priced fully for the deal that's been announced plus the remarkable results in RP. As the doubts fade larger a larger investors will want a slice of the pie. Best advice ....... "Keep Calm and Carry On"

Hi Rhodi Thanks for clearing that up for me. I just expect the RNS to show up on here. Its been so quite on the VRP board that I hadn't checked for a while. I'm 50/50 on wether this will ever become the promised breakthrough drug. Still holding some shares but well down and would need it to be at six pounds a share to get anywhere near to break even. Chester

Morning C7 I noted your comment on the fact none of the regulars are laying claim that any recent buys are theirs and I think I have the answer. The 6 / 5p share price has been like an "all you can eat buffet" to us serious Scalpers. So it just gets to the point where your eyes are be bigger than your wallet...ha ha All the best...

I totally missed the news release on Tuesday 9th April 2019 about the European Patent.

''The granting of this important patent adds a further layer of protection to ensifentrine as a novel potential treatment for COPD," said Verona Pharma chief executive officer Jan-Anders Karlsson.

"We remain focused on completing the final Phase 2b clinical trials with ensifentrine before advancing into Phase 3 in 2020."

Karlsson said ensifentrine had been administered to more than 800 people, and had generated "strong" efficacy data and been well-tolerated.

"We believe this first-in-class dual PD3 and PD4 inhibitor can address a clear unmet medical need in COPD and has significant commercial potential."

Due to the recent lack of any news coming from the company I would have thought that this warranted an RNS.

It's positive news and is also future proofing any potential product.

Why the downplay , I can't compute.

Chester.

'Blinking Heck' news has spread, we're even being touted at Camden Market.... ha ha...

Just been through the exact same journey for nearly four years with Reneuron. Whilst the company worked on getting the science right the share price was hammered and professional decryers dragged the LSE board down as low as possible. Any positivity was relentlessly ridiculed. I've done my own homework on Scancell and with results already proven with SCIB 1, I know that the potential here is very very real. Why we stand at 5p is a mystery to my reasoning of what the company should be worth. My only explanation is because we're on the AIM stock market. It's a market where patience is in short supply but the herd moves big on news, reported potential deals and results. Scancell will have its day, that's my belief and I do have the patience to be here when it does. The strength of the published science is far to solid to be 'Snake Oil'..... DYOR Chester

Ruck Please remove all sharp implements from your immediate surroundings..... Lol

Should read... Share price pounds 2.33 Current M-Cap 75million, Speculative 300million

The best price gauge here is the "Market Capitalisation". Even with an SP of £2.33 the M-Cap sits below £75m. With the current good news from the US trial into RP we can expect some kind of deal being announced. What would be a fair target for the M-Cap at that point? I think possible £300m, does anyone else have a speculative target in mind? Chester

Next financial update will probably be at the AGM which is due around the end of May. Chester..

Thanks C7 It just amazes me that the actual detail / reason for the delay is not stated publicly or have I just missed that piece of info. Chester

Through contact with the company, loose talk at the bar, mates in the USA or an employee at Ichor does anyone have an inclination as to what exactly the hold up is or when it could possibly be approved? ..

The excitement here is that the science is working. Obviously it's early days, but..... Given that the eye sight in the patients treated so far actually stabilises or continues to improve then this is a major breakthrough. It gives real value to the technology and means there is a very good chance that other unmet clinical issues, such as stroke, can be turned around. Having initially bought at 3.5 & 4.0p I sold out when the share price dropped to just over a £ 1.15 but fortunately bought some back at 96p. I was kicking myself for a second time when 'Purpleackey' was constantly predicting 50p or lower. Anyway I am so pleased that I had the faith to hold on and I'm so impressed with the scientists that have created this amazing technology. So my advice is stick not twist.... Chester.

I thought that a cold hard look at where Scancell actually are would help to focus attention on the reality of trying to develop a new technology. The continual bickering on subject matter we have no full and accurate knowledge of has become very wareing. The day that Scancell are able and willing to pop this boards "unreality bubble" in my opinion can't come to soon. Chester

Positives: 1) Bloody good Tech. 2) Top scientific brains 3) Proven with SCIB 1 trial. 4) Patent Protected 5) Lindy wins Swedish Award 6) Links with Immuno Powerhouses. 7) Collaborations with Immuno Powerhouses. 8) Multiple Platforms / Targets. Frustrations: 1) Trial dates delayed. 2) No updates from company. 3) Share Price way to low. 4) No appitite for the shares. 5) Need of money on the radar. 6) Problem with Institutional Investor causing downward pressure on stock price. Negatives : 1) Private Shareholders have no patience. All Technical analysis done at night school so fully Bona Fido Chester.....

If its gets Rene back up to £3.00 share kums can be as excited as he / she likes..... There is a lot of cashing in of profits but some of the new buys are substantial sums. That tells me that there are serious discussions going on about Reneuron being the real deal and larger traders / investors are jumping aboard. These clinical results are remarkable especially for the people in the trial. All the best, Chester

Hi KUMS I've not seen you so excited since Oxford Bio went from 2.5p to 13p. Rene has the initial clinical results that could be just as transformational. Getting back to the old 3p (£3.00)to 6p (£6.00) range would be a great start. Chester

I don't think I deserve that response. Chester